Company overview
INmune Bio is a clinical-stage biotechnology company developing therapies that modulate the innate immune system for cancer and Alzheimer's disease. Key products include XPro1595 (DN-TNF platform) in Phase 2 for early Alzheimer's with inflammation biomarkers and cancer, and INKmune for metastatic castration-resistant prostate cancer. The company has multiple late-stage assets with upcoming regulatory milestones, including FDA interactions for Alzheimer's and rare diseases.
INmune Bio Inc. is listed in the NovaPharmaNews Supplier Hub in the life-science supply chain serving United States & Americas. Core focus areas include inmune bio, innate immune therapy, alzheimer's treatment, prostate cancer therapy, dn-tnf inhibitor.
Structured facts
- Website
- https://www.inmunebio.com
- Markets served
- United States & Americas
- Keywords
- inmune bio, innate immune therapy, alzheimer's treatment, prostate cancer therapy, dn-tnf inhibitor
Products & technologies
Markets served
Company timeline
- — Profile published on NovaPharmaNews
Frequently asked questions
- What are INmune Bio's main therapeutic platforms and pipeline?
- INmune Bio targets innate immune system components with DN-TNF platform (XPro1595 for Alzheimer's and cancer), INKmune for metastatic castration-resistant prostate cancer, and CORDStrom for recessive dystrophic epidermolysis bullosa. Multiple assets are in late-stage development with near-term regulatory milestones.
- What are the latest clinical trial results for XPro in Alzheimer's?
- In the Phase 2 MINDFuL trial, XPro showed cognitive (EMACC effect size 0.27), behavioral, and biomarker (pTau217) benefits in amyloid-positive early AD patients with two or more inflammation biomarkers (n=100), despite missing primary endpoint in broader mITT population (n=200). Company plans FDA Breakthrough Therapy Designation and End-of-Phase 2 meeting.
- What is the regulatory and geographic status of INmune Bio's programs?
- Trials like CaRe Prostate (Phase I/II for INKmune) are US-based. Company intends FDA BLA submission for CORDStrom in RDEB, Breakthrough Designation for XPro in AD, and engagement with UK, EU regulators. Products like XPro are administered via weekly subcutaneous injection.
Related editorial coverage
- Bristol Myers' Innovative Approach to Alzheimer's Beyond Amyloid
- AC Immune Advances ACI-24 Alzheimer's Trial to Final Cohort, Initiates ACI-19764 Phase 1 Study
- AC Immune Initiates Final Cohort in Phase 1b/2 ABATE Trial for Anti-Abeta Alzheimer's Treatment
- FDA Approves Synapton: Breakthrough for Severe Alzheimer's Treatment
- Nexalin Technology Advances FDA Strategy for Alzheimer's Treatment Following U.S. and China Leadership Meetings
- FDA Approves CogniMax: New Early-Stage Alzheimer's Treatment
Explore lab tools and QA/QC resources for R&D teams.
